Conditions: 98.8% · tirzepatide · WXT.
The failure mode I am trying to avoid is making this decision emotionally.
I have twelve months in view and I would like the plan to survive that long.
What would you do, and what would make you change course?
Conditions: 98.8% · tirzepatide · WXT.
The failure mode I am trying to avoid is making this decision emotionally.
I have twelve months in view and I would like the plan to survive that long.
What would you do, and what would make you change course?
The part that matters: the honest answer is that the achievable range of plausible purity figures for a given vial is wider than most people expect.
The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.
Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.
The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.
One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.
Compare purity within a single laboratory on the same method, never across laboratories.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsReporting threshold is convention and not chemistry, which is why two certificates with different thresholds disagree by a tenth of a point or more.
Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.
On the detail: integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.
Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.
The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.
edited 24 Aug 2024 by nine_point_nine — added the placebo-arm figures
Identity and purity are orthogonal, and a high purity says almost nothing about whether the peak is actually what you think it is.
Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.
Buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.
The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.
If you are ranking vendors, specify a method and have all samples tested at the same place.
Gradient slope is the most powerful parameter and almost nobody mentions it, which is why two reports on the same material disagree by a point.
Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.
Compare purity within a single laboratory on the same method, never across laboratories.
edited 22 Sept 2024 by fib4_reader — added the method parameters
Area percentage is not mass percentage, and conflating the two is the most common misreading of a purity figure.
Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.
Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.
The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.